1. Happy Thanksgiving from Cafepharma! Our news staff will be off on Thursday, and will be feeding news on a limited basis throughout the holiday weekend. CP Today will return on Monday, November 30. We hope you enjoy this time, and stay safe! — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Retrophin to buy Orphan Tech for $90M upfront

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 22, 2020 at 11:32 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Retrophin (NASDAQ:RTRX) has agreed to acquire privately-held Orphan Technologies and add OT-58, a novel enzyme replacement therapy in Phase 1/2 trial for the treatment of classical homocystinuria (HCU), a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events.

    article source